฿16.50
+฿0.30(+1.85%)
data.updated
v2.stock.overview v2.daily.trading v2.range.52w
key.stats
yesterday.close฿16.14
market.size฿2.11B
volume.trade1.13M
pe.ratio7.46
div.yield0.00%
diluted.eps2.25
net.income฿287.20M
revenue฿283.05M
earnings.date2026-07-30
eps.estimate0.21
rev.estimate฿80.93M
shares.out131.15M
beta1.434
about.stock
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
sectorHealthcare
industryBiotechnology
ceoKevin C. Tang
headquartersEdmonton,BC,CA
employees128.00
avg.revenue฿2.21M
income.per.emp฿2.24M
stock.faq
stock.price
x
current.stats
52w.range.q
x
pe.ratio.q
x
market.cap.q
x
eps.recent.q
x
buy.sell.q
x
price.factors
x
buy.how
x
risk.warn
risk.notice
disclaimer2
risk.disclosure